- Home
- INBX
INBX
Inhibrx Inc.
as 07-26-2024 4:00pm EST
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what they believe to be the most appropriate agonist function.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 186.4M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 168.4K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.61 - $18.95 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Inhibrx Inc. (INBX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Eckelman Brendan P. | INBX | Chief Scientific Officer | May 28 '24 | Sell | $34.30 | 300,000 | $10,290,000.00 | 1,735,553 | SEC Form 4 |
Latest Inhibrx Inc. News
INBX Breaking Stock News: Dive into INBX Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing
MT Newswires
2 months ago
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi
PR Newswire
2 months ago
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
PR Newswire
3 months ago
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
PR Newswire
3 months ago
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
Zacks
5 months ago
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
PR Newswire
5 months ago
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Zacks
6 months ago
Will Corcept (CORT) Beat Estimates Again in Its Next Earnings Report?
Compare INBX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INBX Inhibrx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.